Literature DB >> 7280966

Phenytoin-dexamethasone interaction: a previously unreported observation.

L A Lawson, R A Blouin, R B Smith, R P Rapp, A B Young.   

Abstract

A possible drug interaction between phenytoin and dexamethasone was evaluated by comparing serum phenytoin concentrations in 23 patients receiving both drugs with those of a control group of 15 patients receiving phenytoin only. Serum phenytoin concentrations obtained 24 hours after a loading dose of 11 mg per kilogram body weight administered intravenously and 13 mg/kg given intramuscularly were examined. The total amounts of dexamethasone administered during the 24-hour period ranged from 16 to 150 mg. The average serum phenytoin concentration was 17.28 +/- 3.49 micrograms/ml in patients receiving both drugs, as compared to 12.48 +/- 3.52 micrograms/ml in patients receiving only phenytoin (p less than 0.001). Our results suggest that serum phenytoin concentrations should be monitored in patients receiving concurrent dexamethasone therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7280966     DOI: 10.1016/s0090-3019(81)80054-7

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  10 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery.

Authors:  Iris Zachenhofer; Markus Donat; Stefan Oberndorfer; Karl Roessler
Journal:  J Neurooncol       Date:  2010-06-06       Impact factor: 4.130

Review 3.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

Review 4.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 5.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

Review 6.  Treatment options for brain metastases in patients with non-small-cell lung cancer.

Authors:  Sadaf Taimur; Martin J Edelman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

Review 7.  Brain metastases.

Authors:  P Y Wen; J S Loeffler
Journal:  Curr Treat Options Oncol       Date:  2000-12

Review 8.  Antiepileptic Drugs in the Management of Cerebral Metastases.

Authors:  Meredith A Monsour; Patrick D Kelly; Lola B Chambless
Journal:  Neurosurg Clin N Am       Date:  2020-10       Impact factor: 2.509

Review 9.  Treatment options for brain metastases in patients with non-small cell lung cancer.

Authors:  Sadaf Taimur; Martin J Edelman
Journal:  Curr Treat Options Oncol       Date:  2003-02

10.  Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.

Authors:  Daniel A Lim; Phiroz Tarapore; Edward Chang; Marlene Burt; Lenna Chakalian; Nicholas Barbaro; Susan Chang; Kathleen R Lamborn; Michael W McDermott
Journal:  J Neurooncol       Date:  2009-01-24       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.